Zhijing Finance APP News, Jinling Pharmaceutical (000919.SZ) released the 2024 interim report. During the reporting period, the company achieved revenue of 1.511 billion yuan, a year-on-year growth of 4.83%. Achieved net income attributable to shareholders of the listed company of 51.8188 million yuan, a year-on-year decrease of 33.16%. Achieved net income attributable to shareholders of the listed company after deducting non-recurring gains and losses of 45.2629 million yuan, a year-on-year decrease of 36.04%. Basic earnings per share were 0.0913 yuan.

Performance driving factors during the reporting period: With the government increasing investment in medical services, the depth and breadth of medical insurance coverage continue to improve. Factors such as the large and aging population, accelerated aging, and increased health awareness of the people promote consumer spending in the healthcare industry. During the reporting period, the overall operation of the company is consistent with the industry development characteristics. The main driving factors of performance are: first, the company's key product sales capabilities have been enhanced through brand advantages and product efficacy; second, as policies and market conditions change, with the profit space of medical institutions being compressed again, the overall number of outpatient and inpatient visits in the company's affiliated medical institutions has stabilized, and medical services are being carried out in an orderly manner.